Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Blog
October 31, 2026
Diabetic macular ischemia means the tiny blood vessels that feed the macula, the center of the retina, have closed or lost blood flow. Diabetic macular edema means damaged vessels have leaked fluid into the macula and made it swell [1,2].
Edema can often be dried up with eye injections, but there is no proven treatment that restores lost macular blood flow. That is why ischemia can limit how much sharp vision comes back, even when the swelling is gone [2,3,4].
This article is general education. It does not replace an exam by your eye doctor or retina specialist, who can tell which problem is affecting your eye.
Key takeaways
In this article
Most changes from macular ischemia are slow. Some symptoms in a diabetic eye are not, and they need fast care [1,3,5,6].
Call 911 if:
Go to an eye emergency service or ER now if you have:
Call your eye doctor the same day if:
Do not wait for a planned monitoring visit if something new happens. Our guide to urgent vision changes covers other warning signs.
Diabetic macular ischemia (DMI) is loss of blood flow in the small capillaries of the macula, caused by diabetes. It shows up as an enlarged or ragged foveal avascular zone and patches of closed capillaries. Over time, the nerve cells these vessels feed can die, and that vision loss may not recover [2].
The retina is the light-sensing layer at the back of the eye. The macula is its center, used for reading, faces and fine detail. The fovea is the very center of the macula and gives the sharpest sight.
The fovea has a small spot with no capillaries at all. This is called the foveal avascular zone, or FAZ. A FAZ is normal. In DMI, the FAZ grows larger and its edge breaks up, and gaps appear between the capillaries around it [2,7].
Ischemia is most common in eyes with advanced diabetic retinopathy, such as the proliferative stage [2]. Our article on the four stages of diabetic retinopathy explains those stages.
Diabetic macular edema (DME) is swelling of the macula caused by fluid leaking from damaged retinal blood vessels into the tissue. It blurs the sharp central vision used for reading and faces. About 1 in 15 people with diabetes develop DME over time, according to the National Eye Institute [1].
Doctors often describe DME as center-involved or not center-involved, depending on whether the swelling reaches the fovea. Anti-VEGF injections, such as aflibercept, bevacizumab and ranibizumab, can stop leaks and help dry the macula [3].
Our separate guide to diabetic macular edema treatment covers injection drugs, laser and steroids in detail. This article focuses on how ischemia differs and why it matters.
The table below sums up the main differences. These are patterns, not strict boxes, and many eyes have features of both.
| Feature | Diabetic macular ischemia | Diabetic macular edema |
|---|---|---|
| Main problem | Closed or missing capillaries; too little blood flow | Leaky vessels; fluid and swelling |
| Best test | Fluorescein angiography or OCT angiography | Structural OCT scan |
| Typical scan finding | Enlarged, irregular foveal avascular zone; dark areas with no flow | Thickened retina with fluid pockets (cysts) |
| Main treatment | No approved treatment to restore flow; treat related disease | Anti-VEGF injections, steroids or laser in selected cases |
| Can vision improve? | Lost function often does not return | Often improves when fluid clears |
| Main outlook factor | How large and central the flow loss is, and whether it grows | How long fluid was present and how much retinal damage it left |
Yes. The two often occur together in the same eye. In two large ranibizumab trials, about 1 in 4 eyes treated for DME also had areas of closed macular capillaries at the start. A 2026 real-world study of more than 1,000 eyes found ischemia in about 24% of eyes with DME [4,8].
Swelling can hide what lies beneath it. Sometimes the full extent of ischemia becomes clear only after the fluid is gone. That is one reason a doctor may order angiography when vision stays poor despite a dry OCT.
Both conditions can cause blurred central vision, trouble reading, faded colors or contrast, and a smudge near the center of what you look at. Symptoms alone cannot tell you which problem you have. Early on, either one may cause no symptoms at all, which is why regular diabetic eye exams matter [1].
A letter chart measures only one part of sight. You may read a small line in the clinic but still struggle in dim light. A short list of tasks that have become harder helps your doctor link scans to daily life.
Macular ischemia is diagnosed with angiography, which maps blood flow in the retina. Fluorescein angiography uses an injected dye. OCT angiography uses repeated light scans and no dye. A regular OCT scan shows fluid and retinal layers but cannot directly show blood flow, so it is used alongside angiography [9,10].
The diabetic eye exam guide explains each test step by step. Here is what each one shows for these two conditions.
Optical coherence tomography (OCT) takes cross-section pictures of the retina, a bit like slices of bread. It is the main test for macular edema. It shows fluid pockets, measures thickness and tracks how the macula responds to treatment.
OCT can also show damage linked to poor vision. One sign is disorganization of the retinal inner layers, called DRIL, where the inner layers lose their normal borders. In eyes with DME, more DRIL went with worse vision [11]. A 2026 study also linked DRIL with macular ischemia [4].
For fluorescein angiography (FA), a yellow dye is injected into a vein, usually in the arm. A camera takes photos as the dye moves through the retinal vessels. FA shows both leakage and areas where vessels do not fill [10].
FA is generally safe. You may feel brief nausea or warmth, and your urine can look dark or orange for a day or two. A review of studies found mild reactions in up to about 18% of people and severe reactions in under 0.6%. A past reaction to fluorescein is the main known risk factor [10,12].
Tell the team before the test if you are pregnant, have had a dye reaction, or have allergies [10].
OCT angiography (OCTA) scans the same spot many times and detects the motion of blood cells. It needs no injection. It can show separate capillary layers at different depths, which FA cannot do well [9].
OCTA has limits. It cannot show leakage, so it does not replace FA for every question. Very slow flow may look like no flow [9]. In one study of trial images, 97% of OCTA scans had at least one artifact. About half had artifacts severe enough to affect the numbers [13].
FA and OCTA also do not always agree. One study found only low to fair agreement between them when grading macular ischemia [14].
OCTA reports often include FAZ area and vessel density. These numbers differ between machines, so results from different devices cannot be compared directly [15]. A change on a printout may be real disease, or a change in scan quality or device.
FAZ size also varies between healthy people. In one large FA study, the median FAZ was 0.19 square millimeters in eyes without ischemia and 0.78 in eyes with severe ischemia [7]. Your doctor reads the number together with the image and your vision.
Anti-VEGF injections reduce leakage and swelling, but they do not rebuild capillaries that have closed. Nerve cells that lost their blood supply may already be damaged. So when ischemia sits near the fovea, vision may improve less than expected after the fluid clears, or reach a lower final level [2,4,16].
Small studies show this pattern. In one bevacizumab study, half of eyes with ischemia lost at least one line of vision at 3 months. Only 21% of eyes without ischemia did [16]. In another, eyes with ischemia had no significant vision gain at 6 months, even though the swelling went down [17].
Larger data give a more hopeful picture. In an analysis of the RIDE and RISE trials, eyes with closed macular capillaries started with worse vision. With monthly ranibizumab, they still gained a similar number of letters as eyes without it [8].
A 2026 study of 1,004 eyes in routine care found the same balance. Eyes with ischemia improved with injections but had worse vision throughout follow-up. The authors concluded that ischemia did not stop treatment from working [4].
So ischemia mainly lowers the ceiling for recovery. It is not, on its own, a reason to skip injections for edema that is affecting sight. Studies disagree on whether injections change macular blood flow, so this remains a research question [18].
A dry OCT means the fluid is gone. It does not mean the macula is healthy. Ischemia, DRIL, past damage to light-sensing cells, cataract and other eye problems can all keep vision blurred [4,11].
In this case, ask whether angiography would help explain the result. Extra injections may not help if the main problem is lost blood flow rather than fluid.
The outlook depends on how severe the ischemia is, how close it is to the fovea and whether it keeps growing. In a large study, mild ischemia was not linked with worse chart vision. Moderate and severe ischemia were. Ischemia that grows over time raises the risk of losing vision [7,19].
In a study of eyes with established ischemia, the FAZ grew by about 5% to 10% of its size each year. More severe ischemia at the start predicted faster growth. Eyes whose ischemia progressed were more likely to lose vision [19].
Ischemia near the nerve fiber bundle between the macula and the optic nerve was also strongly linked with poor vision [7]. Your doctor will look at where the flow loss is, not just how large it is.
A DMI diagnosis does not mean you will go blind. Its course differs from person to person. Ask your doctor what is stable now and what would change the plan.
As of October 2026, there is no approved treatment that reopens closed macular capillaries or slows DMI. Care focuses on treating any edema or proliferative disease, managing blood sugar, blood pressure and cholesterol, and protecting the vision you have. New drugs are being tested in clinical trials [2,3].
Your retina specialist may still treat other problems in the same eye. That can include injections for edema or treatment for abnormal new vessels. Our article on diabetic retinopathy injections, laser and surgery explains those options.
Managing blood sugar, blood pressure and cholesterol is the main way to keep diabetic eye disease from getting worse [3]. It will not reverse established ischemia, but it helps protect both eyes and your overall health.
HORNBILL was the first clinical trial of a drug for DMI, according to its authors. It studied BI 764524, an injected antibody that blocks a protein called semaphorin 3A. The small study met its safety goals. It found no meaningful changes in vision or retinal thickness, and it was too short and small to show benefit [2].
A larger phase II study of the same drug in diabetic retinopathy was still recruiting as of October 2026 [20]. Until such trials report, treat claims that any product "restores circulation" in the macula with caution.
If central vision stays limited, vision rehabilitation can help you make the most of the sight you have. Options include magnifiers, brighter lights, anti-glare glasses and phone or computer settings that enlarge text or read aloud [21].
You can ask for this help while medical treatment continues. Ask your eye doctor for a low vision referral if daily tasks have become hard. Our guide to low vision tools and rehabilitation has practical ideas.
Netra Restoration Therapy (NRT) is an adjunctive program that combines acupuncture and Oriental medicine principles. It is offered alongside your retina specialist's care, never instead of it. You can read what NRT involves on our site.
NRT has not been tested in controlled trials for diabetic macular ischemia or macular edema. There is no evidence that it reopens closed capillaries, dries macular fluid or replaces injections, laser or surgery. Do not delay or skip any recommended eye treatment. Our page on how NRT effectiveness is assessed explains how we discuss evidence and outcomes.
Macular ischemia is loss of blood flow in the tiny capillaries of the macula, the part of the retina used for sharp central vision. In diabetes, these capillaries can close over time. The nerve cells they feed may then stop working, which can cause blurred central vision that may not recover.
In people with diabetes, long-term high blood sugar damages the small retinal vessels until some close. This loss of flow is most common in advanced diabetic retinopathy. Other conditions can also reduce macular blood flow, so your doctor will check for other causes when findings are unusual.
As of October 2026, no approved treatment reverses diabetic macular ischemia or reopens closed capillaries. Some vision can improve when coexisting edema is treated. Early trials of new drugs are under way, but none has shown that it restores vision.
Anti-VEGF injections treat leakage and swelling, not lost blood flow. Eyes with both edema and ischemia can still gain vision with injections, but they often finish with worse vision than eyes without ischemia. Ischemia alone is not usually a reason to stop injections for edema.
Doctors diagnose macular ischemia with fluorescein angiography, which uses an injected dye, or OCT angiography, which uses light scans without dye. They look for an enlarged, irregular foveal avascular zone and areas with no capillary flow. A regular OCT scan helps but cannot show blood flow on its own.
Severe ischemia at the center of the macula can cause lasting loss of central vision. Mild ischemia often leaves good chart vision. A diagnosis is not a forecast of total blindness, and low vision aids can help people use the sight they have.
No. Diabetic macular ischemia is caused by diabetes damaging the macula's blood vessels. Age-related macular degeneration is a different disease linked with aging and changes under the retina. Both affect central vision, but their tests and treatments differ.
Sources checked October 31, 2026.
This article provides general education and does not replace an individual eye examination, diagnosis or treatment plan. Sudden vision loss, a shower of new floaters, flashes, a curtain over your vision, or pain and redness after an eye injection needs emergency eye care today.
